Takeaways: Tevimbra’s completed pCPA negotiations strengthen BeOne’s position in Canada’s NPC immunotherapy market and could establish an early publicly funded first-line option. Prov...
Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for Tevimbra + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metastatic...
